The new AAP schedule provides guidance for routine immunization against 18 diseases, including updates for RSV, influenza, and COVID-19 immunization.

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

The original NDA submission included data from the registration-directed phase 3 MOVE-FA trial as well as 2 long-term studies evaluating vatiquinone in FA.

Semaglutide linked to increased risk of nonarteritic anterior ischemic optic neuropathy, but evidence remains insufficient to establish definitive conclusion.

The extension was needed to review newly submitted long-term clinical data for all patients in the pivotal study following an FDA information request.

Pemvidutide is currently being evaluated in the phase 2 RECLAIM study, which is enrolling approximately 100 patients with AUD and obesity or overweight.

HealthDay News — Differences across blood pressure (BP) measurement methods show clinically important variance in readings, according to a review published online August 19 in the Annals of Internal ...

In October 2024, Imuldosa received approval from the Food and Drug Administration based on data from the phase 3 Opportuniti study.